Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 473

1.

Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.

Parisi C, Mastoraki S, Markou A, Strati A, Chimonidou M, Georgoulias V, Lianidou ES.

Clin Chim Acta. 2016 Aug 7;461:156-164. doi: 10.1016/j.cca.2016.08.003. [Epub ahead of print]

PMID:
27510924
2.

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.

Ann Oncol. 2016 Aug 8. pii: mdw274. [Epub ahead of print]

PMID:
27502729
3.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2016 Aug 4. [Epub ahead of print]

PMID:
27492015
4.

Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group.

Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V.

Clin Lung Cancer. 2016 Jun 2. pii: S1525-7304(16)30114-0. doi: 10.1016/j.cllc.2016.05.009. [Epub ahead of print]

PMID:
27397849
5.

Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

Matikas A, Kentepozidis N, Georgoulias V, Kotsakis A.

Clin Lung Cancer. 2016 Jun 2. pii: S1525-7304(16)30111-5. doi: 10.1016/j.cllc.2016.05.006. [Epub ahead of print] Review.

PMID:
27341790
6.

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).

Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A; HORG’s Lung Cancer Working Group.

Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7. Epub 2016 Jun 22.

PMID:
27335027
7.

Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer.

McLoed AG, Sherrill TP, Cheng DS, Han W, Saxon JA, Gleaves LA, Wu P, Polosukhin VV, Karin M, Yull FE, Stathopoulos GT, Georgoulias V, Zaynagetdinov R, Blackwell TS.

Cell Rep. 2016 Jun 28;16(1):120-32. doi: 10.1016/j.celrep.2016.05.085. Epub 2016 Jun 16.

8.

Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.

Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V.

J Geriatr Oncol. 2016 Jun 2. pii: S1879-4068(16)30053-4. doi: 10.1016/j.jgo.2016.05.002. [Epub ahead of print]

PMID:
27264267
9.

Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.

Markou A, Zavridou M, Sourvinou I, Yousef G, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chem. 2016 Jul;62(7):1002-11. doi: 10.1373/clinchem.2015.253716. Epub 2016 May 19.

PMID:
27197674
10.

Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer.

Koinis F, Vetsika EK, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V, Kotsakis A.

J Thorac Oncol. 2016 Aug;11(8):1263-72. doi: 10.1016/j.jtho.2016.04.026. Epub 2016 May 10.

PMID:
27178984
11.

Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients.

Matikas A, Georgoulias V, Kotsakis A.

Expert Opin Emerg Drugs. 2016 Jun;21(2):157-66. doi: 10.1080/14728214.2016.1184646. Epub 2016 May 17.

PMID:
27139914
12.

Distinct features of circulating microparticles and their relationship with disease activity in inflammatory bowel disease.

Voudoukis E, Vetsika EK, Giannakopoulou K, Karmiris K, Theodoropoulou A, Sfiridaki A, Georgoulias V, Paspatis GA, Koutroubakis IE.

Ann Gastroenterol. 2016 Apr-Jun;29(2):180-7. doi: 10.20524/aog.2016.0010.

13.

A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.

Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V, Agelaki S.

Cancer Chemother Pharmacol. 2016 May;77(5):949-56. doi: 10.1007/s00280-016-2997-7. Epub 2016 Mar 19.

PMID:
26994909
14.

Small cell lung cancer (SCLC): no treatment advances in recent years.

Koinis F, Kotsakis A, Georgoulias V.

Transl Lung Cancer Res. 2016 Feb;5(1):39-50. doi: 10.3978/j.issn.2218-6751.2016.01.03. Review.

15.

SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.

Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S, Georgoulias V, Lianidou E.

Clin Chem Lab Med. 2016 Aug 1;54(8):1385-93. doi: 10.1515/cclm-2015-0776.

PMID:
26741346
16.

The Management and Costs of Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer in Greece.

Kousoulakou H, Boukovinas I, Georgoulias V, Kosmidis P, Koumakis G, Makrantonakis P, Samantas E, Syrigos K, Krikelis D, Markouri A, Geitona M.

Value Health. 2015 Nov;18(7):A451. doi: 10.1016/j.jval.2015.09.1138. Epub 2015 Oct 20. No abstract available.

PMID:
26532537
17.

Palliative chemotherapy for patients with breast cancer.

Saloustros E, Georgoulias V.

Lancet Oncol. 2015 Nov;16(15):1453-4. doi: 10.1016/S1470-2045(15)00399-X. Epub 2015 Oct 22. No abstract available.

PMID:
26482276
18.

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2015 Aug 19;17:113. doi: 10.1186/s13058-015-0624-x.

19.

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.

Kourlaba G, Rapti V, Alexopoulos A, Relakis J, Koumakis G, Chatzikou M, Maniadakis N, Georgoulias V.

BMC Health Serv Res. 2015 Aug 5;15:307. doi: 10.1186/s12913-015-0971-4.

20.

Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.

Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D.

BMC Cancer. 2015 Jul 24;15:542. doi: 10.1186/s12885-015-1562-9.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk